Drug Trial Radar · NCT03905512
A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy
Last checked: Nov 20, 2026Latest source record: Oct 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
170
Actual
Start
May 7, 2019
Primary completion
Aug 5, 2020
Study completion Aug 5, 2020
Sponsor
- Lead sponsor
- Selecta Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, parallel-arm, multicenter study to compare the safety and efficacy profiles of SEL-212 and KRYSTEXXA®. Participants will be randomized 1:1 to receive treatment with SEL-212 or KRYSTEXXA® for 6 months. Efficacy assessments, as measured by serum uric acid (SUA) levels, will be conducted at intervals that are appropriate to determine treatment effect differences. Safety will be monitored throughout the study.
Conditions
- Chronic Gout
Interventions
SEL-212Drug
Administered as specified in the treatment arm
KRYSTEXXA®Drug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Serum Uric Acid (SUA) Reduction of < 6 mg/dL for at Least 80% of the TimeTime frame: Up to Month 6
Locations
43 sites in 1 country. Site status is shown where the registry gives one.
Pinnacle Research Group, LLC
Anniston, Alabama
Arizona Arthritis & Rheumatology Research, PLLC
Sun City, Arizona
Baptist Health Center for Clinical Research
Little Rock, Arkansas
Medvin Clinical Research
Covina, California
Valerius Medical Group and Research Center of Greater Long Beach, Inc.
Los Alamitos, California
Arthritis Care and Research Center
Poway, California
MD Strategies Research Centers
San Diego, California
Clinical Research of West Florida
Clearwater, Florida
QPS-Medical Research Assoc LLC
Miami, Florida
Well Pharma Medical Research Corp.
Miami, Florida
Panax Clinical Research
Miami Lakes, Florida
Accelerated Enrollment Solutions (AES)
Orlando, Florida
Rheumatology Associates of Central Florida, PA
Orlando, Florida
Clinical Research of West Florida, Inc.
Tampa, Florida
Advent Health Group Multispecialty at Habana and Bruce B. Downs
Tampa, Florida
Arthritis Center of North Georgia
Gainesville, Georgia
Better Health Clinical Research, Inc.
Newnan, Georgia
Institute of Arthritis Research
Idaho Falls, Idaho
Great Lakes Clinical Trials
Chicago, Illinois
L-MARC Research Center
Louisville, Kentucky
Klein & Associates, M.D., P.A.
Cumberland, Maryland
Klein & Associates, M.D., P.A.
Hagerstown, Maryland
The Center for Rheumatology and Bone Research
Wheaton, Maryland
Clinical Pharmacology Study Group
Worcester, Massachusetts
University Hospital
Ann Arbor, Michigan
Elite Clinical Research, LLC
Jackson, Mississippi
TEST
Blue Springs, Missouri
NYU Langone Ambulatory Care Brooklyn Heights
Brooklyn, New York
DJL Clinical Research
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Cape Fear Arthritis Care PLLC
Leland, North Carolina
Cape Fear Arthritis Care PLLC
Leland, North Carolina
New Horizons Clinical Research
Cincinnati, Ohio
Arthritis & Rheumatology Center of Oklamhoma, PLLC
Oklahoma City, Oklahoma
Altoona Center for Clinical Research
Duncansville, Pennsylvania
Clinical Research Center of Reading, LLC
Wyomissing, Pennsylvania
West Tennessee Research Institute, LLC
Jackson, Tennessee
Amarillo Center for Clinical Research
Amarillo, Texas
Austin Regional Clinic
Austin, Texas
Tekton Research
Austin, Texas
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.